Our case highlights that LADA may account for failure of diabetes remission after bariatric surgery and also demonstrates that LADA should be considered in all patients with T2D, in whom glycemic control actually deteriorates after bariatric surgery.
Analysis of combined data from both studies identified several prognostic factors associated with poor outcome, including age <6 months at diagnosis, with the most inferior outcome in those <3 months, CD10 negativity, failure of morphological remission on day 14 marrow, WBC >50 × 10/l at diagnosis and presence of the t(4 11) MLL rearrangement.
Furthermore, androgenic compounds can induce a remission after failure of antiestrogenic therapy (reviewed in [ 19]).
In the present study we analyzed two groups of patients with generalized WG: patients with active disease (failure of immunosuppression) and patients in remission (responding to immunosuppressive therapy).
It was concluded that the variability in clinical definitions of either treatment failure or remission seems to have been attributed mainly to the time at which assessments were made, making it difficult to determine what these actually mean in clinical practice [ 2].
In a meta-analysis of oral 5-ASA formulations for the maintenance of remission of UC, the Peto OR for the failure to maintain clinical or endoscopic remission for oral 5-ASA versus placebo was 0.47 (95% CI, 0.36 to 0.62).
Patients with t(4 14) MM demonstrate a shorter duration of remission and more aggressive relapses characterized by renal failure, cytopenia and extramedullary disease.
The presence of dual mechanisms of demyelination may be responsible for the failure of immunosuppression to promote long-term remission in many MS patients.
There is broad consensus that high-grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous nephropathy.
Based on the results of the models, disease was dichotomized into "early stage" (untreated patients and patients in complete remission) and "advanced stage" (patients with induction failure, partial remission or active relapse at the time of transplantation).
